FY2021 Overview and FY2022 Forecast

Dr. Osamu Okuda,
President & CEO

FY2021 Consolidated Financial Overview (Core)

Toshiaki Itagaki,
Executive Vice President & CFO

Overview of Development Pipeline

Tetsuya Yamaguchi,
Executive Vice President, Head of Project & Lifecycle Management Unit

Chugai’s Research Policy/Chugai’s Mid-Size Molecule Drug Discovery

Hitoshi Iikura Ph.D., Head of Research Div.

Update on Antibody Engineering Technologies

Tomoyuki Igawa Ph.D., Head of Translational Research Div.

Sustainability Management

Motoo Ueno, Representative Director & Deputy Chairman

Materiality and ESG Ratings

Toshiaki Itagaki, Executive Vice President & CFO

ESG in the Context of Growth Strategy Drug Development in Pursuit of Sustainable Healthcare

Tsukasa Kusano, Vice President, Head of Clinical Development Div.

ESG in the Context of Growth Strategy Global Environmental Initiatives (Pharmaceutical Technology)

Shigehiro Yamada, Ph. D., Head of Sustainability Dept.

FY2021 3Q Overview

Dr. Osamu Okuda,
President & CEO

FY2021 3Q Consolidated Financial Overview (Core)

Toshiaki Itagaki,
Executive Vice President & CFO

Overview of Development Pipeline

Tetsuya Yamaguchi,
Senior Vice President, Head of Project & Lifecycle Management Unit

Overview of Evrysdi^®

Hideto Kodaira,
Evrysdi Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.

Evrysdi^®, a New Treatment Option for Spinal Muscular Atrophy (SMA): The First Oral SMA Drug

Kayoko Saito, MD, PhD,
Professor of Special Appointment, Institute of Medical Genetics, Tokyo Women’s Medical University

Product Overview

Satoru Ito,
Lifecycle Leader, Foundation Medicine Unit, Chugai Pharmaceutical Co., Ltd.

Current Status of Cancer Genomic Medicine in Japan and Expectations for FoundationOne^® Liquid CDx Cancer Genomic Profile

Takayuki YOSHINO, MD, PhD,
Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East (NCCE), Japan

Striving to Develop Therapeutic Drugs for COVID-19

Dr.Osamu Okuda,
President & CEO, Chugai Pharmaceutical Co., Ltd.

Product Overview of RONAPREVE^™ Intravenous Infusion Set

Satoshi Aida,
Ph.D., RONAPREVE Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.

Confronting COVID-19

Prof. Kazuhiro Tateda M.D., Ph.D.,
Department of Microbiology and Infectious Disease, Toho University School of Medicine

FY2021 2Q Overview

Dr. Osamu Okuda,
President & CEO

FY2021 2Q Consolidated Financial Overview (Core)

Toshiaki Itagaki,
Executive Vice President & CFO

Overview of Development Pipeline

Tetsuya Yamaguchi,
Senior Vice President, Head of Project & Lifecycle Management Unit

Polivy^® Intravenous Infusion 30mg/140mg

Dr. Takaki Koga,
POLIVY^® Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.

Treatment Options for Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Koji Izutsu, M.D., Ph.D.,
Department of Hematology, National Cancer Center Hospital

FY2021 1Q Overview

Dr. Osamu Okuda,
President & CEO

FY2021 1Q Consolidated Financial Overview (Core)

Toshiaki Itagaki,
Executive Vice President & CFO

Overview of Development Pipeline

Tetsuya Yamaguchi,
Senior Vice President, Head of Project & Lifecycle Management Unit

Review of 2020 and General Overview of IBI 21

Tatsuro Kosaka,
Chairman & CEO

FY2020 Consolidated Financial Overview (Core)

Toshiaki Itagaki,
Executive Vice President & CFO

Overview of Development Pipeline

Tetsuya Yamaguchi,
Senior Vice President, Head of Project & Lifecycle Management Unit

New Growth Strategy for 2030

Dr. Osamu Okuda,
President & COO

CHUGAI DIGITAL VISION 2030

Satoko Shisai, Vice President, Head of Digital & IT Supervisory Div.

Innovation in the Drug Discovery Process Using AI

Dr. Hiroyuki Tsunoda, Head of Discovery Technology Dept., Research Div.

Utilization of Real World Data

Dr. Nobuya Ishii, Head of Science & Technology Intelligence Dept., Project & Lifecycle Management Unit

Digital Marketing Strategy

Takato Shimauchi, Head of Customer Solution Dept., Marketing & Sales Div.

FY2020 3Q Consolidated Financial Overview

Toshiaki Itagaki,
Executive Vice President and CFO

Overview of Development Pipeline

Dr. Minoru Hirose,
Head of R&D Portfolio Management Dept.,
Project & Lifecycle Management Unit

Progress in sustainability-oriented management and strategies

Motoo Ueno, Representative Director & Deputy Chairman

Deep-dive theme 1: Sustainability-related Indicators

Toshiaki Itagaki, Executive Vice President & CFO

Deep-dive theme 2: Long-term Planning

Shigehiro Yamada, Ph.D., Head of Sustainability Dept.

Deep-dive theme 3: Examples of Shared Value Creation

Keiji Kono, Senior Vice President,
In charge of External Affairs Dept. and Global Health Policy

Product Overview of ENSPRYNG^® Subcutaneous Injection 120 mg Syringe

Katsuhiro Hara,
ENSPRYNG^® Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.

Current Status of the Treatment for Neuromyelitis Optica Spectrum Disorders (NMOSD) and Expectations for ENSPRYNG

Prof. Kazuo Fujihara, M.D.
Department of Multiple Sclerosis Therapeutics, Fukushima Medical University School of Medicine

Aiming to Achieve the Mid-term Business Plan “IBI 21”
- FY2020 Half Year Results -

Tatsuro Kosaka,
Chairman and CEO

FY2020 2Q Consolidated Financial Overview

Toshiaki Itagaki,
Executive Vice President and CFO

Overview of Development Pipeline

Dr. Minoru Watanabe,
Vice President, Head of Project & Lifecycle Management Unit

FY2020 1Q Consolidated Financial Overview

Toshiaki Itagaki,
Executive Vice President and CFO

Overview of Development Pipeline

Dr. Minoru Hirose,
Head of R&D Portfolio Management Dept.,
Project & Lifecycle Management Unit

Mid-term Business Plan “IBI 21”
- 2019 Results and 2020 Strategic Policies -

Tatsuro Kosaka,
President and CEO

FY2019 Consolidated Financial Overview

Toshiaki Itagaki,
Executive Vice President and CFO

Overview of Development Pipeline

Dr. Yasushi Ito,
Executive Vice President and Co-Head of Project & Lifecycle Management Unit

Chugai’s Strategy for Drug Discovery Research

Junichi Nezu, PhD,
General Manager of Research Division
Chugai Pharmaceutical Co., Ltd.

Chugai’s Antibody Engineering Technologies for Innovative Drug Discovery

Tomoyuki Igawa, PhD,
CEO and Research Head, Chugai Pharmabody Research Pte. Ltd.

FY2019 3Q Consolidated Financial Overview

Toshiaki Itagaki,
Executive Vice President, CFO

Overview of Development Pipeline

Dr. Minoru Hirose,
Department Manager of R&D Portfolio Management Dept

Product Overview of Rozlytrek^®

Yoshito Nakanishi,
Rozlytrek^® Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.

From organ specific to gene specific cancer treatment
- Expectations on ROZLYTREK for NTRK Fusion-Positive Solid Tumors -

Takayuki Yoshino, MD, PhD
Director, Department of Gastroenterology and Gastrointestinal Oncology,
National Cancer Center Hospital East (NCCE), Japan
Co-principal investigator, GI-SCREEN-Japan

Aiming to Achieve the Mid-term Business Plan “IBI 21”
- FY2019 Half Year Results -

Tatsuro Kosaka,
President and CEO

FY2019 2Q Consolidated Financial Overview

Toshiaki Itagaki,
Executive Vice President and CFO

Overview of Development Pipeline

Dr. Yasushi Ito,
Executive Vice President and Co-Head of Project & Lifecycle Management Unit

1. FoundationOne^® CDx Cancer Genomic Profile Product Overview

Kosuke Iijima, Department Manager of Foundation Medicine Business Dept., Foundation Medicine Unit

2. Cancer Genomic Medicine
- Clinical Implementation and Challenges -

Prof. Muto Manabu, Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University

Motoo Ueno, Representative Director, Deputy Chairman

FY2019 1Q Consolidated Financial Overview

Toshiaki Itagaki,
Executive Vice President & CFO

Overview of Development Pipeline

Dr. Minoru Hirose,
Department Manager of R&D Portfolio Management Dept.,
Project & Lifecycle Management Unit

New Mid-term Business Plan “IBI 21”

Tatsuro Kosaka,
President and CEO

FY2018 Consolidated Financial Overview (IFRS based)

Toshiaki Itagaki,
Executive Vice President and CFO

Overview of Development Pipeline

Dr. Yasushi Ito,
Executive Vice President and Co-Head of Project & Lifecycle Management Unit

1. Product Overview of GAZYVA^® Intravenous Infusion 1000 mg

Naoko Oya, GAZYVA^® Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.

2. Pathology of Follicular Lymphoma and Clinical Trial Results of obinutuzumab

Kiyohiko Hatake, M.D., Ph.D.
Deputy Director, Head of the Malignant Tumor and Hematologic Tumor Center at the International University of Health and Welfare, Mita Hospital, Japan

FY2018 3Q Consolidated Financial Overview (IFRS based)

Toshiaki Itagaki,
Executive Vice President & CFO

Overview of Development Pipeline

Dr. Minoru Hirose,
Department Manager of R&D Portfolio Management Dept.,
Project & Lifecycle Management Unit

Aiming to Achieve Mid-term Business Plan “IBI 18”
- FY2018 Half Year Results -

Tatsuro Kosaka,
President and CEO

FY2018 2Q Consolidated Financial Overview (IFRS based)

Toshiaki Itagaki,
Executive Vice President and CFO

Overview of Development Pipeline

Dr. Yasushi Ito,
Executive Vice President and Co-Head of Project & Lifecycle Management Unit

1. HEMLIBRA^® Subcutaneous Injection Product Overview

Hiroshi Motegi, HEMLIBRA^® Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.

2. Current Status of Hemophilia Treatment and Expectations for HEMLIBRA^®

Prof. Midori Shima, M.D., Ph.D.
Department of Pediatrics, Nara Medical University

1. TECENTRIQ^® Intravenous Infusion 1200mg Product Overview

Mikio Sakai, TECENTRIQ^® Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.

2. The Anti-PD-L1 Antibody Tecentriq^® Mode of Action and Future Outlook

Hiroyoshi Nishikawa, M.D., Ph.D.
Department of Immunology, Nagoya University Graduate School of Medicine
Exploratory Oncology Research & Clinical Trial Center, Research Institute, National Cancer Center

3. Treatment Overview of Non-Small Cell Lung Cancer and Clinical Trials for Tecentriq^®

Yuichiro Ohe, M.D.
Deputy Director, Chief,
Division of Thoracic Oncology
National Cancer Center Hospital, Japan

Aiming to Achieve Mid-Term Business Plan “IBI 18”
-2017 Results and 2018 Outlook-

Tatsuro Kosaka, President, COO

FY2017 Consolidated Financial Overview

Yoshio Itaya, Executive Vice President, CFO

Overview of Development Pipeline

Yasushi Ito, Senior Vice President,
Head of Project & Lifecycle Management Unit

Drastic Changes in the Environment of the New Drug Creation and Challenges Facing Japan’s Pharmaceutical Industry

Chairman and CEO　Osamu Nagayama

FY2017 2Q Consolidated Financial Overview

Yoshio Itaya,
Executive Vice President, CFO

Overview of Development Pipeline

Yasushi Ito,
Senior Vice President, Head of Project & Lifecycle Management Unit

Mid-Term Business Plan “IBI 18”
-2016 Results and 2017 Outlook-

Tatsuro Kosaka, President, COO

FY2016 Consolidated Financial Overview

Yoshio Itaya, Executive Vice President, CFO

Overview of Development Pipeline

Yasushi Ito, Senior Vice President,
Head of Project & Lifecycle Management Unit

Reorganization to Provide a New Solution

Susumu Kato, Senior Vice President,
General Manager of Marketing & Sales Div.

FY2016 2Q Consolidated Financial Overview

Yoshio Itaya,
Executive Vice President CFO

Overview of Development Pipeline

Minoru Watanabe,
Associate Vice President
Deputy General Manager of Research Division

Outline of the Comprehensive Collaboration Agreement between Osaka University and Chugai Pharmaceutical Co., Ltd.

Executive Vice President of Research and Risk Management, Osaka University
Yasushi Yagi

Outline of Comprehensive Collaboration with IFReC

CHUGAI PHARMACEUTICAL CO., LTD.
Executive Vice President
Yutaka Tanaka

1. Product Overview of Bonviva^® Tablet

Takeshi Sakaguchi
Bonviva^® Product Manager
Chugai Pharmaceutical Co., Ltd.

2. Bonviva^® Tablet: Clinical Utility and Our Expectation

Hiroshi Hagino, M.D., Ph.D., Professor
School of Health Science
Tottori University Faculty of Medicine, Japan

New Mid-Term Business Plan "IBI 18"

Tatsuro Kosaka, President, COO

FY2015 Consolidated Financial Overview

Yoshio Itaya, Executive Vice President, CFO

Overview of Development Pipeline

Yutaka Tanaka, Executive Vice President

FY2015 2Q Consolidated Financial Overview

Yoshio Itaya, Executive Vice President CFO

Overview of Development Pipeline

Yutaka Tanaka, Executive Vice President

1. Overview of ZELBORAF^®

Takahiro Mizui
ZELBORAF^® Lifecycle Leader
CHUGAI PHARMACEUTICAL CO., LTD.

2. cobas^® BRAF V600 Mutation Test

Toru Ogawa
Manager, Molecular Diagnostics
Roche Diagnostics K.K.

3. ZELBORAF^® tablet Postmarketing safety measures

Shin Yoshida
Pharmacovigilance Department
CHUGAI PHARMACEUTICAL CO., LTD.

4．Overview of melanoma and clinical trials of vemurafenib

Naoya Yamazaki, M.D., Ph.D.
Chief, Dept. of Dermatologic Oncology
National Cancer Center Hospital, Japan

Aiming to Become a Top Pharmaceutical Company

Tatsuro Kosaka, President, COO

FY2014 Consolidated Financial Overview

Yoshio Itaya, Executive Vice President, CFO

Overview of Development Pipeline

Yutaka Tanaka, Executive Vice President,
Head of Project & Lifecycle Management Unit